



Deposited via The University of Sheffield.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/215422/>

Version: Published Version

---

**Article:**

Alexander, H., Malek, R., Prieto-Merino, D. et al. (2024) A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register. *British Journal of Dermatology*, 191 (6). pp. 988-999. ISSN: 0007-0963

<https://doi.org/10.1093/bjd/ljae287>

---

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.

# A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK–Irish A-STAR register

Helen Alexander<sup>1</sup>, Rayka Malek<sup>1</sup>, David Prieto-Merino<sup>1,2</sup>, Elizaveta Gribaleva<sup>1</sup>, Manisha Baden<sup>1</sup>, Paula Beattie<sup>3</sup>, Sara Brown<sup>4</sup>, Tim Burton<sup>5</sup>, Shona Cameron<sup>1</sup>, Bola Coker<sup>6</sup>, Michael J Cork<sup>7</sup>, Ross Hearn<sup>8</sup>, John R Ingram<sup>9</sup>, Alan D Irvine<sup>10,11,12</sup>, Graham A Johnston<sup>13</sup>, Alice Lambert<sup>14</sup>, Mark Lunt<sup>15</sup>, Irene Man<sup>16</sup>, Louise Newell<sup>17</sup>, Graham Ogg<sup>18</sup>, Prakash Patel<sup>1</sup>, Mandy Wan<sup>19,20</sup>, Richard B Warren<sup>21</sup>, Richard Woolf<sup>22</sup>, Zenas ZN Yiu<sup>21</sup>, Nick Reynolds<sup>23</sup>, Michael R Ardern-Jones<sup>24</sup> and Carsten Flohr<sup>1</sup> on behalf of the UK-Irish A-STAR study group

<sup>1</sup>Unit for Paediatric & Population-Based Dermatology Research, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, UK

Correspondence: Carsten Flohr. Email: [carsten.flohr@kcl.ac.uk](mailto:carsten.flohr@kcl.ac.uk)

The full author list is repeated, along with the author affiliations, in [Appendix 1](#).

Full details of the A-STAR Study Group are provided in [Appendix 2](#).

## Abstract

**Background** The main conventional systemic treatments for atopic dermatitis (AD) are methotrexate (MTX) and ciclosporin (CyA). Dupilumab was the first novel systemic agent to enter routine clinical practice. There are no head-to-head randomized controlled trials or real-world studies comparing these agents directly. Network meta-analyses provide indirect comparative efficacy and safety data and have shown strong evidence for dupilumab and CyA.

**Objectives** To compare the real-world clinical effectiveness and safety of CyA, dupilumab and MTX in AD.

**Methods** We compared the effectiveness and safety of these systemic agents in a prospective observational cohort study of adult and paediatric patients recruited into the UK–Irish Atopic eczema Systemic Therapy Register (A-STAR). Treatment effectiveness measures included Eczema Area and Severity Index (EASI), Patient-Oriented Eczema Measure (POEM), Peak Pruritus Numerical Rating Scale (PP-NRS), Dermatology Life Quality Index (DLQI) and children's DLQI (cDLQI). The minimum duration of treatment was 28 days and follow-up was 12 months. Adjusted Cox-regression analysis was used to compare the hazard ratios of achieving EASI-50, EASI-75 and EASI-90 over time, and linear mixed-effects models were used to estimate changes in efficacy scores. Treatment safety was assessed by examining adverse events (AEs) at follow-up visits.

**Results** We included 488 patients (311 adults and 177 children/adolescents) on dupilumab ( $n=282$ ), MTX ( $n=149$ ) or CyA ( $n=57$ ). CyA and MTX were primarily used as the first-line treatment, while dupilumab was mainly a second-line systemic treatment as per UK National Institute of Clinical and Care Excellence (NICE) recommendations. EASI-50, EASI-75 and EASI-90 were achieved more rapidly in the dupilumab and CyA groups compared with MTX. After adjustment for previous severity, the reduction in EASI, POEM, PP-NRS and DLQI was greater for patients treated with dupilumab compared with MTX. In patients with severe disease the reduction in EASI, POEM and PP-NRS was even greater with CyA. The incidence rates of AEs were similar across groups (734, 654 and 594 per 10 000 person-month on CyA, dupilumab and MTX, respectively).

**Conclusions** This real-world comparison of CyA, dupilumab and MTX in AD suggests that dupilumab is consistently more effective than MTX and that CyA is most effective in very severe disease within 1 year of follow-up.

Accepted: 6 July 2024

© The Author(s) 2024. Published by Oxford University Press on behalf of British Association of Dermatologists. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

### Lay summary

Atopic dermatitis (AD) is a common skin disease which causes dry and itchy skin. AD affects around one in five children and one in 10 adults in the UK. The main conventional systemic treatments are with drugs called methotrexate (MTX) and ciclosporin (CyA). As well as these, dupilumab was the first novel systemic agent to enter routine clinical practice. However, there are no studies that have directly compared the effectiveness or safety of these treatments. This study aimed to compare the effectiveness and safety of CyA, dupilumab and MTX. We compared these treatments in adults and children with AD who were participating in the UK-Irish Atopic eczema Systemic TherApy Register (A-STAR). Treatment effectiveness was assessed using the Eczema Area and Severity Index (EASI), and with patient-reported severity scores for itch and quality of life. Patients were treated for a minimum of 28 days and followed up for 12 months. Treatment safety was determined by patient-reported side-effects at follow-up visits. A total of 488 patients were assessed, including 282 patients on dupilumab, 149 on MTX and 57 on CyA. We found that the time taken for AD severity EASI scores to reduce by 50%, 75% and 90% was shorter for patients on dupilumab and CyA, compared with MTX. Improvements in itch and quality of life were greater for patients treated with dupilumab, compared with MTX. In patients with severe AD, improvement was even greater than with CyA. The incidence of side-effects was similar with dupilumab, CyA and MTX treatments. Overall, our findings suggest that dupilumab is consistently more effective than MTX and that CyA is most effective in very severe disease within 1 year of follow-up.

### What is already known about this topic?

- The conventional systemic agents ciclosporin (CyA) and methotrexate (MTX) have been used to treat atopic dermatitis (AD) for decades.
- Dupilumab was the first novel systemic agent for AD to enter routine clinical practice, and several trials have demonstrated its efficacy and safety.
- Network meta-analyses have shown strong indirect comparative efficacy and safety profiles for dupilumab and CyA but there are no head-to-head trials comparing these agents directly.

### What does this study add?

- This real-world effectiveness and safety comparison in adult and paediatric AD found that patients treated with dupilumab and CyA experience a greater reduction in Eczema Area and Severity Index, Patient Oriented Eczema Measure and itch compared with those treated with MTX.
- There was a similar incidence of adverse events with all three medications.

Atopic dermatitis (AD) affects up to 20% of children and 10% of adults and has a major impact on quality of life.<sup>1,2</sup> Most patients can be treated effectively with emollients and topical anti-inflammatory agents. However, around 5% require systemic immunomodulatory therapies to induce disease remission and long-term control.<sup>3</sup>

Conventional systemic AD treatments include methotrexate (MTX) and ciclosporin (CyA). Most clinicians find that conventional systemic immunomodulatory therapies cannot be used for many years because of adverse events (AEs) or intolerance. The development of novel agents with improved long-term safety profiles is therefore needed.

Dupilumab was the first novel systemic AD treatment to enter routine clinical practice. Several phase III randomized controlled trials (RCTs) have demonstrated its efficacy and safety profile, compared with placebo, for adults, children and young people with AD.<sup>4</sup> These trials included carefully selected patients who were managed under strictly controlled conditions, which limits the generalizability of the findings to real-world dermatology practice.

In real-world practice these treatments tend to be used for slightly different clinical presentations of AD. CyA is often used as a short-term and fast-acting rescue treatment in more severe AD when rapid disease control is needed; it is often stopped within a year to avoid AEs. In contrast,

MTX and dupilumab are typically used for more long-term disease control.

Recent AD registry-based studies have shown clinical effectiveness outcomes and safety profiles of dupilumab to be consistent with RCT results in adults.<sup>5–10</sup> Ocular symptoms, including conjunctivitis, are the most significant side-effects of dupilumab. However, to the best of our knowledge, the real-world effectiveness and safety of dupilumab have not yet been shown in comparison to CyA and MTX. Apart from small studies comparing MTX with CyA and azathioprine, which showed comparable effectiveness,<sup>11–13</sup> there are very few head-to-head comparisons of systemic AD therapies. Recent RCTs comparing dupilumab and the Janus kinase (JAK) inhibitors in adult AD found abrocitinib<sup>14</sup> to have comparable efficacy to dupilumab while upadacitinib<sup>15</sup> showed superior efficacy after 16 weeks of treatment.

An indirect analysis comparing adult dupilumab registry data with historical real-world conventional systemic data showed dupilumab has a longer drug survival than MTX and CyA.<sup>16</sup> Network meta-analyses (NMAs) provide further indirect comparative efficacy and safety data for systemic therapies in AD, and have shown dupilumab and high-dose CyA were similarly effective and superior to MTX and azathioprine.<sup>17–19</sup> However, the data for NMAs are extracted from

published RCTs, and the findings are therefore also limited by the constraints of the RCT setting and patient selection criteria. Comparative studies of systemic AD therapies are lacking.

The UK–Irish Atopic eczema Systemic TherApy Register (A-STAR) is a prospective, multicentre register of paediatric and adult patients with AD treated with systemic immunomodulatory drugs. The study provides real-world data on the use of systemic therapies in AD, enabling the evaluation of drug effectiveness and safety beyond the confines of short-term RCTs.

The aim of this study was to compare the real-world clinical effectiveness and safety profile of CyA, dupilumab and MTX in paediatric and adult AD.

## Patients and methods

### Study design

A prospective observational cohort study was performed to compare CyA, dupilumab and MTX treatment outcomes, using data from the UK–Irish A-STAR register. All patients who started CyA, dupilumab or MTX treatment between 1 October 2018 and 30 October 2023 were examined, but only treatment courses lasting 28 days or more were used for the effectiveness analysis. Patients were aged 3–82 years and fulfilled the UK Working Party's AD diagnostic criteria. Patients on more than one systemic treatment at the same time were not included. Patients also used concomitant topical therapy including corticosteroids, calcineurin inhibitors and emollients in the context of routine clinical care, as prescribed by their local physician.

Patients were assessed at baseline, 4 and 12 weeks after starting treatment, and at 12-weekly intervals thereafter. Patient characteristics assessed at baseline included demographics, comorbidities (including delayed and immediate allergies), prior AD treatments and concomitant medications. This study was carried out in accordance with the latest World Medical Association Declaration of Helsinki (2013 amendment). Participants, or in the case of children and adolescents, their parents/carer, provided written informed consent at study enrolment. The study is covered by research ethics committee reference no. 18/WA/0200, ISRCTN 11210918.

### Outcome measures

Treatment effectiveness was assessed using validated physician-assessed and patient-reported outcome measures at baseline and all follow-up visits. Physician-assessed severity was measured by the Eczema Area and Severity Index (EASI, 0–72). Patient-reported outcome measures included the Patient-Oriented Eczema Measure (POEM, 0–28), Peak Pruritus Numerical Rating Scale (PP-NRS, 0–10), Dermatology Life Quality Index (DLQI, 0–30) for those aged 16 years and older, and the children's DLQI (cDLQI, 0–31) for younger patients. EASI-50 ( $\geq 50\%$  improvement in EASI score from baseline), EASI-75 ( $\geq 75\%$  improvement in EASI score from baseline) and EASI-90 ( $\geq 90\%$  improvement in EASI score from baseline) were calculated for each group. Treatment safety was assessed by examining AEs

at all follow-up visits. The relatedness to the drug of the AEs was assessed by the treating physician using MedDRA pharmacovigilance coding, as is standard practice in treatment registers and clinical trials. AEs occurring during the treatment course only were recorded and risk windows were not implemented.

### Statistical analysis

Baseline patient characteristics, treatment duration and safety data were summarized using descriptive statistics. Fisher's exact test was used to compare the baseline distributions of categorical variables.

Patients with treatment courses of more than 28 days were included in the effectiveness analysis and patients were followed up for a maximum of 12 months. The baseline value for each outcome measure (EASI, POEM, PP-NRS and DLQI) was the latest score recorded within a 28-day window *before* treatment initiation. If there was no measurement within 28 days prior to treatment initiation, the first score measured within 28 days after starting treatment was used. From the survival analysis below we excluded 132 treatment runs for which the baseline EASI was not available within the specified windows.

### Survival analysis

To compare the speed at which each treatment group achieved EASI-50, EASI-75 and EASI-90 over time we used three separate Cox-regression models. The outcome event was whether at each visit the EASI score had reached a reduction from baseline of 50%, 75% or 90%, for each model, respectively. All models were adjusted for age, sex, ethnicity (White/non-White), number of previous systemic treatments received and baseline EASI.

### Predictive change analysis

To account for the effect of disease severity on treatment effectiveness, we modelled the predicted change in disease severity scores between consecutive visits where outcome = (following score – current score)/(months between visits). We used linear mixed-effects models with the interaction between mean-centred current score and the treatment as key explanatory variables, and adjusted for age, sex, ethnicity (White/non-White), treatment duration, number of previous treatments and a random-effect term by individual to account for repeated measures.

To compare the treatment effectiveness in paediatric AD, a subgroup analysis, using the same survival and consecutive change analysis, was performed on participants under the age of 18 years. A complete case analysis was conducted and missing data were not imputed. All analyses were conducted using R 3.4.1 computational software.<sup>20</sup>

## Results

### Baseline patient characteristics

We included 488 patients [mean (SD) age 27.4 (15.6) years] and their baseline characteristics are summarized in Table 1. Of these 488 patients, 217 (44.5%) were female; 282 (mean age 28.8 years, 44% female) were treated with dupilumab,

**Table 1** Baseline patient characteristics

Variable	Ciclosporin N=57	Dupilumab N=282	Methotrexate N=149
Sex, n (%)			
Female	28 (49.1)	124 (44.0)	65 (43.6)
Male	29 (50.9)	155 (55.0)	84 (56.4)
Unknown	0 (0)	3 (1.0)	0 (0)
Ethnicity, n (%)			
White	45 (78.9)	203 (72.0)	110 (73.8)
Asian	6 (10.5)	38 (13.5)	23 (15.4)
Black	1 (1.8)	16 (5.7)	6 (4.0)
Other	4 (7.0)	21 (7.4)	6 (4.0)
Mixed	0 (0)	1 (0.4)	3 (2.0)
Unknown	1 (1.8)	3 (1.1)	1 (0.7)
Age in years, mean (SD)	28.1 (15.8)	28.8 (15.2)	24.5 (15.9)
Age categories, n (%)			
0–10	9 (15.8)	14 (5.0)	32 (21.5)
11–15	6 (10.5)	56 (19.9)	28 (18.8)
16–18	2 (3.5)	32 (11.3)	8 (5.4)
19–25	9 (15.8)	44 (15.6)	25 (16.8)
26–35	13 (22.8)	56 (19.9)	21 (14.1)
36–45	11 (19.3)	31 (11.0)	19 (12.8)
> 45	7 (12.3)	49 (17.4)	16 (10.7)
Treatment duration in months, mean (SD)	8.0 (7.98)	17.9 (14.2)	13.7 (12.6)
Past treatments, n (%)			
0	22 (38.6)	17 (6.0)	78 (52.3)
1	18 (31.6)	121 (42.9)	47 (31.5)
2	7 (12.3)	71 (25.2)	16 (10.7)
+3	10 (17.5)	73 (25.9)	8 (5.4)
EASI, mean (SD)	22.3 (12.5)	19.1 (13.6)	18.0 (11.4)
PP-NRS, mean (SD)	7.3 (1.95)	6.1 (2.6)	6.7 (2.4)
POEM, mean (SD)	19.3 (7.3)	17.8 (7.9)	19.2 (6.8)
DLQI, mean (SD)	14.7 (7.6)	13.8 (8.6)	14.7 (7.97)
cDLQI, (mean (SD)	11.7 (7.5)	12.0 (7.7)	14.0 (7.4)
Follow-up time (person-month)	458.0	5052.4	2045.3

cDLQI, Children's DLQI; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; POEM, Patient Oriented Eczema Measure; PP-NRS, Peak Pruritus Numerical Rating Scale.

149 (mean age 24.5 years, 44% female) received MTX, and 57 (mean age 28.1 years, 49% female) were treated with CyA.

While most baseline characteristics were similar across study groups, there were some differences between the treatment groups. The mean age of patients treated with dupilumab was higher than those treated with MTX ( $P < 0.009$ ). More patients receiving dupilumab had received treatment with a prior systemic agent than those treated with CyA (94% vs. 61%  $P < 0.0001$ ) or MTX (94% vs. 48%  $P < 0.0001$ ). The baseline mean PP-NRS score was lower in the dupilumab group than in the CyA group (6.1 vs. 7.3  $P < 0.001$ ) and the MTX group (6.1 vs. 6.7  $P < 0.032$ ). Patients were on CyA treatment for a significantly shorter mean duration (8.0 months) than those on MTX (13.7 months) and dupilumab (17.9 months).

The systemic treatment dosing regimens followed clinical practice and ranged from 1.4 to 5 mg kg<sup>-1</sup> daily of CyA and 5–25 mg weekly of MTX. The most common dose for adults on dupilumab was 300 mg every 2 weeks. The most common dose for children on dupilumab was 200 mg every 2 weeks, with some patients on 200 mg every 3 weeks, 200 mg every 4 weeks and 200 mg every 8 weeks.

## Treatment effectiveness


### Survival analysis

Raw and adjusted survival curves can be seen in Figure 1 and the hazard ratios (HRs) from Cox models in Table 2. In

summary, CyA achieves EASI-50, EASI-75 and EASI-90 more rapidly than dupilumab, which in turn achieves these three outcomes more rapidly than MTX (all point estimates of HRs are positive). The statistically significant differences are between CyA and MTX in EASI-50, EASI-75 and EASI-90 ( $P < 0.0005$ ,  $P < 0.021$  and  $P < 0.0007$ , respectively); between CyA and dupilumab in EASI-50 ( $P < 0.014$ ); and between dupilumab and MTX in EASI-75 and EASI-90 ( $P < 0.04$  and  $P < 0.0016$ , respectively). The unadjusted HRs between treatment groups of achieving EASI-50, EASI-75 and EASI-90 are shown in Table S1 (see [Supporting Information](#)).

### Effectiveness adjusting for disease severity

To guide clinical decision-making between physicians and patients, linear models were additionally used to predict changes in severity score with each treatment after a visit. The regression lines in Figure 2 show that the higher the disease severity at a visit, the greater the expected reduction in severity is at the next visit. This holds for all four severity outcomes and the three treatments and is partly explained by the well-known regression-to-the-mean effect. There is significant evidence that the strength of this effect (the slope of the line) differs by treatment in the models for EASI ( $P < 0.0006$ , Figure 2a), showing that the lines are closer together at lower EASI scores but deviate from each other as the EASI increases. The POEM (Figure 2b) and PP-NRS (Figure 2c) model lines for dupilumab and MTX are more or less parallel with dupilumab always below (i.e. more



**Figure 1** The proportion of patients on ciclosporin (CyA), dupilumab (DUP) and methotrexate (MTX) achieving EASI-50, EASI-75 and EASI-90 over time. Kaplan–Meier analysis: (a) unadjusted and (b) adjusted for age, sex, ethnicity, number of previous treatments and baseline EASI.

effective) than MTX, while CyA has a stronger slope cutting through the other two. This suggests that at high POEM and PP-NRS scores CyA might be more effective than dupilumab, while at low scores it might be less effective than MTX. In DLQI the pattern is similar but the slope of the CyA line is less pronounced and the difference between slopes is not significant ( $P < 0.08$ , Figure 2d).

The tables below each panel in Figure 2 illustrate the estimated difference in effectiveness between treatments at different disease severities. Low, middle and high example values for (a) EASI, (b) POEM, (c) PP-NRS and (d) DLQI scores, which represent the severity range of patients requiring systemic treatment, are shown. The black dashed lines in the figures correspond to these values. The differences between treatments in the estimated score reduction

per month, as estimated by the model, are shown with 95% confidence intervals (CIs).

### Eczema Area and Severity Index

The differences between treatments in reducing EASI, POEM and PP-NRS scores depend significantly on the current score (Figure 2a–c). For example, in patients with an EASI score of 40, those on CyA are expected to benefit from an EASI reduction in the next month 3.97 points larger than in those on dupilumab (95% CI  $-6.97$  to  $-0.97$ ) and 7.05 points larger than in those on MTX (95% CI  $-10.43$  to  $-3.67$ ) given the same age, sex, ethnicity, treatment duration and number of previous treatments (Figure 2a). The EASI reduction in patients with an EASI of 40 on dupilumab is also significantly greater than in those on MTX (3.08 points; the 95% CI  $-5.83$  to  $-0.33$  excludes 0). At EASI = 25, dupilumab and CyA are significantly more effective than MTX (comparison 95% CI excludes 0) but the difference between CyA and dupilumab is not significant. In patients with EASI = 10, there are no significant differences between any treatment comparisons. This corresponds with the three lines converging on the left-hand side of Figure 2a.

### Patient Oriented Eczema Measure, Peak Pruritus Numeric Rating Scale and Dermatology Life Quality Index

Dupilumab performs consistently better than MTX at all levels of severity in all three outcomes as all 95% CIs

**Table 2** Adjusted hazard ratios between treatment groups of achieving EASI-50, EASI-75 and EASI-90; mean (95% confidence interval)


Comparison	EASI-50	EASI-75	EASI-90
Dupilumab – Methotrexate	1.31 (0.93–1.85)	1.55 (1.02–2.36)	3.04 (1.53–6.04)
Ciclosporin – Methotrexate	2.22 (1.42–3.47)	1.97 (1.11–3.50)	4.24 (1.86–9.62)
Ciclosporin – Dupilumab	1.69 (1.12–2.57)	1.27 (0.75–2.17)	1.39 (0.71–2.73)
	$P=0.0004$	$P=0.0204$	$P=0.0006$
	$P=0.0130$	$P=0.3787$	$P=0.3332$

Models adjusted for age, sex, ethnicity, number of previous treatments and baseline Eczema Area and Severity Index (EASI)

comparing dupilumab and MTX have their upper limit below 1.

However, CyA compares with the other two differently depending on the score level. At the highest POEM and

PP-NRS scores, CyA achieves greater reductions than MTX and dupilumab. At mid-level scores, CyA performs somewhere between the other two, and at lower scores CyA performs worse than MTX and dupilumab with statistically significant



**Figure 2** Predicted change in (a) EASI, (b) POEM, (c) PP-NRS and (d) DLQI per month between two consecutive visits in each treatment group. Monthly change in outcome score between consecutive visits [(score in following visit – score in current visit)/(months between visits)] are modelled with a linear mixed-effects model adjusting for the outcome measure at the current visit, age, sex, ethnicity, time on the current treatment and number of previous treatments. The tables below each figure show the estimated difference in effectiveness between treatments at low, middle and high (a) EASI, (b) POEM, (c) PP-NRS and (d) DLQI scores (black dashed lines) at the current visit. ‘Current’ score= outcome measure at the first of two consecutive visits. CI, confidence interval; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; POEM, Patient Oriented Eczema Measure; PP-NRS, Peak Pruritus Numeric Rating Scale

differences. The DLQI pattern is similar to those for POEM and PP-NRS, although CyA is not more effective than dupilumab at improving quality of life at higher DLQI scores. Dupilumab is more effective at reducing DLQI than MTX at any level.

### Paediatric subgroup analysis

The results of the paediatric subgroup analysis are provided in Tables S2 and S3 and Figures S1 and S2 (see Supporting Information).

### Treatment safety

There were a total of 605 AEs reported throughout the study (Table 3). There were no differences in the overall incidence of AEs between treatment groups. In the CyA group, there were 57 AEs in 27 (47.4%) treatment courses (incidence rate 734 per 10 000 person-months). In the dupilumab group there were 395 AEs in 174 (61.7%) treatment courses (incidence rate 654 per 10 000 person-months), compared with 153 AEs in 73 (48.99%) treatment courses (incidence rate 594 per 10 000 person-months) in the MTX arm. Gastrointestinal disorders, including nausea and vomiting, were more common with MTX (incidence rate 244) compared with 136 and 79 per 10 000 person-months for CyA and dupilumab respectively. Eye disorders were more common with dupilumab (incidence rate 274) vs. 82 and 49 per 10 000 person-months for CyA and MTX respectively. Nervous system disorders, mainly headaches, were more common with CyA (incidence rate 190) and reported in 75 and 41 per 10 000 person-months for dupilumab and MTX respectively.

Fifteen serious AEs (SAEs) were reported which led to hospitalization in 11 cases, three life-threatening events and one death (Table 4). Seven of the 15 SAEs occurred in seven of 282 (2%) patients on dupilumab, and all were considered unlikely to be related to the treatment apart from one case of herpes simplex infection. Eight of the 15 SAEs were reported in eight of 149 (5%) patients on MTX, including two events which were considered related to the treatment: one herpes simplex infection and one varicella infection. There were no SAEs reported in the 57 patients on CyA.

### Discussion

The time to achieve EASI-50, EASI-75 and EASI-90 was shorter with dupilumab and CyA than with MTX. When taking into consideration the effect of disease severity on treatment effectiveness, dupilumab was consistently more effective than MTX at all severities and across all four outcomes measures (EASI, POEM, PP-NRS and DLQI). CyA effectiveness was more complex. In very severe disease, CyA tended to achieve greater reductions in outcome scores than dupilumab and MTX (except possibly for DLQI). In less severe disease the effectiveness of CyA was between that of MTX and dupilumab respectively, except with EASI reduction where CyA was still more effective than dupilumab. In more moderate disease, CyA was less effective than dupilumab in all outcomes and not more (sometimes less) effective than MTX. This pattern is consistent with clinical practice in which CyA is often used as an effective rescue treatment to rapidly control very severe disease.

Dupilumab has been shown in real-world monotherapy studies to have a comparable effectiveness to RCT findings in adults and children.<sup>21–23</sup> Real-world studies from the USA<sup>21</sup> and Europe<sup>22</sup> comparing dupilumab with conventional systemics, including CyA and MTX, found increased dupilumab drug survival compared with conventional systemics. However, comparisons of treatment effectiveness and safety were not reported. The recently updated European and American guidelines for the management of atopic dermatitis in adults make strong recommendations for the use of dupilumab and other novel therapies while the conventional systemics including MTX and CyA are only cautiously recommended.<sup>23–25</sup> However, many regulatory bodies, such as the UK National Institute for Clinical and Care Excellence (NICE), stipulate that a conventional systemic agent needs to be tried first, before a novel one can be entertained. This guidance is unlikely to change in the future. In addition, MTX is an affordable systemic treatment option for middle- and low-resource settings.<sup>26</sup>

We found that the differences between treatments in reducing EASI, POEM and PP-NRS between consecutive study visits were dependent on AD severity. The increased effectiveness of CyA compared with MTX and dupilumab in very severe disease reached levels above the minimal clinically important differences (MCIDs) for these measures. For instance, at a high POEM of 25, the expected score reduction with CyA was 3.78 points greater than that with MTX (MCID 3.4 points). Similarly, at a high EASI of 40, the EASI reduction with CyA was 7.05 points greater than that with MTX (MCID 6.6 points).

When comparing treatment effectiveness exclusively in paediatric patients we observed similar trends to those found in the combined adult and paediatric study population. All EASI reductions were more rapidly achieved with dupilumab and CyA than with MTX treatment and we observed similar patterns in EASI changes between consecutive visits after adjustment for severity. Many of these differences between treatments did not reach statistical significance. This is likely to be because of the smaller sample size in the paediatric cohort. Similarly, differences between treatments in PP-NRS reduction were not significant in the paediatric subgroup. Consistent with the combined adult and paediatric analysis, in more severe paediatric AD, CyA was the most effective treatment at reducing patient-assessed severity.

A limitation of this study was the baseline differences between treatment groups, which reflect real-world clinical practice. The CyA group had a higher baseline severity and shorter duration of treatment than the MTX and dupilumab groups. In the comparison of treatment effectiveness, all linear models were adjusted for baseline EASI as well as age, sex, ethnicity (White/non-White) and number of previous systemic treatments received. Future studies with larger populations would allow for stratified analyses according to ethnicity and sex, to further account for these potential confounders. The baseline differences reflect the clinical preference for CyA as short-term and fast-acting rescue treatment in more severe AD when rapid disease control is needed. CyA is often stopped within a year due to AEs or to prevent AEs. This is in contrast with dupilumab, which is mostly well tolerated with long-term use. We acknowledge that these treatments are used in different clinical scenarios and this needs to be considered when applying the results of this comparison study to clinical practice.

**Table 3** The most frequent adverse events (AEs)<sup>a</sup> in the ciclosporin, dupilumab and methotrexate treatment groups

SOC/AE	Dupilumab (n=282) 395 events in 174 (61.7%) TCs IR <sup>b</sup> = 654/10 000 PM			Methotrexate (n=149) 153 events in 73 (48.99%) TCs IR <sup>b</sup> = 594/10 000 PM			Ciclosporin (n=57) 57 events in 27 (47.4%) TCs IR <sup>b</sup> = 734/10 000 PM		
	AEs	TCs, n (%)	IR <sup>b</sup>	AEs	TCs, n (%)	IR <sup>b</sup>	AEs	TCs, n (%)	IR <sup>b</sup>
	<i>Eye disorders</i>								
SOC	75	73 (25.9)	274.4	6	6 (4.0)	48.8	3	3 (5.3)	81.5
Dry eye	13	13 (4.6)	48.9	0	0 (0)	0	0	0 (0)	0
Eye irritation	12	12 (4.3)	45.1	1	1 (0.7)	8.1	0	0 (0)	0
Eye pruritus	9	9 (3.2)	33.8	0	0 (0)	0	1	1 (1.8)	27.2
Noninfective conjunctivitis	18	17 (6.0)	63.9	0	0 (0)	0	1	1 (1.8)	27.2
Ocular hyperaemia	6	6 (2.1)	22.6	0	0 (0)	0	0	0 (0)	0
Ocular surface disease	3	3 (1.1)	11.3	0	0 (0)	0	0	0 (0)	0
<i>Gastrointestinal disorders</i>									
SOC	21	21 (7.4)	78.9	32	30 (20.1)	244.1	5	5 (8.8)	135.9
Abdominal pain	5	5 (1.8)	18.8	4	4 (2.7)	32.6	2	2 (3.5)	54.4
Diarrhoea	3	3 (1.1)	11.3	4	4 (2.7)	32.6	0	0 (0)	0
Mouth ulceration	0	0 (0)	0	3	3 (2.0)	24.4	0	0 (0)	0
Nausea	6	6 (2.1)	22.6	17	15 (10.1)	122.1	0	0 (0)	0
Vomiting	4	4 (1.4)	15.0	2	2 (1.3)	16.3	1	1 (1.8)	27.2
<i>Immune system disorders</i>									
SOC	12	11 (3.9)	41.4	4	4 (2.7)	32.6	1	1 (1.8)	27.2
Anaphylactic reaction	3	3 (1.1)	11.3	2	2 (1.3)	16.3	0	0 (0)	0
Hypersensitivity	3	2 (0.7)	7.5	0	0 (0)	0	1	1 (1.8)	27.2
Seasonal allergy	4	4 (1.4)	15.0	1	1 (0.7)	8.1	0	0 (0)	0
<i>Infections and infestations</i>									
SOC	91	88 (31.1)	330.8	59	55 (36.9)	447.6	12	12 (21.1)	326.1
Acute nasopharyngitis	18	16 (5.7)	60.1	15	14 (9.4)	113.9	2	2 (3.5)	54.4
Conjunctivitis	4	4 (1.4)	15.0	1	1 (0.7)	8.1	0	0 (0)	0
COVID-19	16	16 (5.7)	60.1	10	9 (6.0)	73.2	1	1 (1.8)	27.2
Ear infection	4	4 (1.4)	15.0	1	1 (0.7)	8.1	0	0 (0)	0
Folliculitis	0	0 (0)	0	3	3 (2.0)	24.4	1	1 (1.8)	27.2
Herpes simplex	10	9 (3.2)	33.8	3	3 (2.0)	24.4	0	0 (0)	0
Influenza	4	4 (1.4)	15.0	0	0 (0)	0	0	0 (0)	0
LRTI	7	7 (2.5)	26.3	5	4 (2.7)	32.6	1	1 (1.8)	27.2
Skin infection	8	8 (2.8)	30.1	10	9 (6.0)	73.2	4	4 (7.0)	108.7
<i>Investigations</i>									
SOC	16	16 (5.7)	60.1	4	4 (2.7)	32.6	4	4 (7.0)	108.7
Eosinophil count increased	4	4 (1.4)	15.0	0	0 (0)	0	1	1 (1.8)	27.2
<i>Metabolism and nutrition disorders</i>									
SOC	3	3 (1.1)	11.3	3	3 (2.0)	24.4	0	0 (0)	0
Decreased appetite	1	1 (0.4)	3.8	3	3 (2.0)	24.4	0	0 (0)	0
<i>Musculoskeletal and connective tissue disorders</i>									
SOC	16	16 (5.7)	60.1	4	4 (2.7)	32.6	3	3 (5.3)	81.5
Arthralgia	4	4 (1.4)	15.0	0	0 (0)	0	1	1 (1.8)	27.2
Pain in extremity	4	4 (1.4)	15.0	2	2 (1.3)	16.3	0	0 (0)	0
<i>Nervous system disorders</i>									
SOC	20	20 (7.1)	75.2	5	5 (3.4)	40.7	7	7 (12.3)	190.2
Headache	9	9 (3.2)	33.8	4	4 (2.7)	32.6	2	2 (3.5)	54.4
<i>Psychiatric disorders</i>									
SOC	14	14 (4.95)	52.6	3	3 (2.0)	24.4	2	2 (3.5)	54.4
Depressed mood	3	3 (1.1)	11.3	1	1 (0.7)	8.1	0	0 (0)	0
<i>Respiratory, thoracic and mediastinal disorders</i>									
SOC	18	18 (6.4)	67.7	3	3 (2.0)	24.4	3	3 (5.3)	81.5
Asthma	5	5 (1.8)	18.8	1	1 (0.7)	8.1	0	0 (0)	0
Cough	4	4 (1.4)	15.0	1	1 (0.7)	8.1	1	1 (1.8)	27.2
<i>Skin and subcutaneous tissue disorders</i>									
SOC	68	67 (23.7)	251.8	17	13 (8.7)	105.8	8	8 (14.0)	217.4
Acne	5	5 (1.8)	18.8	0	0 (0)	0	2	2 (3.5)	54.4
Alopecia	9	8 (2.8)	30.1	1	1 (0.7)	8.1	1	1 (1.8)	27.2
Eczema	31	31 (10.99)	116.5	10	7 (4.7)	56.97	3	3 (5.3)	81.5
Erythema	5	5 (1.8)	18.8	0	0 (0)	0	0	0 (0)	0

IR, incidence rate; LRTI, lower respiratory tract infection; PM, person-month; SOC, system organ class; TCs, treatment courses. <sup>a</sup>AEs are based on MedDRA code Preferred Terms. <sup>b</sup>The incidence rate is calculated as number of events over the person-months in the groups ( $\times 10\ 000$ ).

Unlike the CyA and MTX groups, almost all patients treated with dupilumab were not treatment naïve. This is consistent with other real-world studies<sup>27</sup> and reflects the UK NICE recommendation<sup>28</sup> that patients have an inadequate response or

contraindication to treatment with at least one conventional systemic therapy, before dupilumab is prescribed. In practice, most patients on dupilumab will have received treatment with a first-line conventional systemic, such as CyA and MTX, prior

**Table 4** Serious adverse events (SAE)<sup>a</sup> on dupilumab and methotrexate<sup>b</sup>

Treatment/System organ class	SAE	Relatedness to the drug	SAE category
<i>Dupilumab</i>			
Cardiac disorders	Acute myocardial infarction	Unlikely	Death
Immune system disorders	Anaphylactic reaction	Unlikely	Life threatening
	Anaphylactic reaction	Unlikely	Life threatening
Infections and infestations	Herpes simplex	Likely	H/PEH
Injury, poisoning and procedural complications	Fibula fracture	Unlikely	H/PEH
Respiratory, thoracic and mediastinal disorders	Pulmonary embolism	Unlikely	H/PEH
Skin and subcutaneous tissue disorders	Dermatitis exfoliative generalized	Unlikely	H/PEH
<i>Methotrexate</i>			
Immune system disorders	Anaphylactic reaction	Unlikely	H/PEH
	Anaphylactic reaction	Unlikely	Life threatening
Infections and infestations	Skin infection	Unlikely	H/PEH
	Skin infection	Unlikely	H/PEH
	Herpes simplex	Likely	H/PEH
	Varicella	Likely	H/PEH
Injury, poisoning and procedural complications	Accidental overdose	Unlikely	H/PEH
	Joint injury	Unlikely	H/PEH

H/PEH, Hospitalization or prolonged existing hospitalization. <sup>a</sup>SAEs are based on MedDRA code Preferred Terms. <sup>b</sup>No SAEs were reported in any patients on ciclosporin.

to dupilumab, and therefore have partially treated disease with less potential for improvement compared with the MTX and CyA subjects. Although we have adjusted for the number of previous treatments in the statistical analysis, the observed differences in drug effectiveness may partly reflect the more treatment-resistant disease of the dupilumab cohort. We can reason how our estimate would be affected by this potential bias. If we assume our dupilumab-treated patients have more treatment-resistant disease, we would expect that our dupilumab cohort would show an underestimation of the 'true' effect of dupilumab in a group of more treatment-naïve patients, comparable with those in our MTX cohort. Despite this underestimation, dupilumab still shows greater effectiveness than MTX in all outcomes. Therefore, the true difference in effectiveness between dupilumab and MTX is likely to be even greater in favour of dupilumab.

While there were no differences in total AE incidence between treatment groups, specific AE subtypes were associated with each treatment. Gastrointestinal disorders were more frequent in the MTX group, eye disorders were more frequent in the dupilumab group, and neurological AEs, mainly headaches, were more frequent with CyA, all AE profiles known to be associated with these systemic therapies.<sup>27,29–32</sup> Interestingly, we did not see increased renal impairment and dyslipidaemia in the CyA cohort. This may be due to the short duration of treatment in this group, suggesting that the treatment was stopped before the onset of these AEs. The incidence of AEs in the dupilumab group was higher than has been previously reported. This may partly be because some patients in the A-STAR register who were started on dupilumab were prescribed prophylactic eye drops and warned about the potential side-effect of eye irritation. This may have alerted patients to this possible side-effect and increased the likelihood of AE reporting in this group. The follow-up period and sample size in this study are relatively modest and not sufficiently powered to conclusively report SAEs. Future analysis of more participants, over longer time periods and with linked Hospital Episode Statistics data, is needed.

Further real-world studies are needed to validate the findings of this study, also comparing dupilumab with other

novel biologics and JAK inhibitors. Recent real-world monotherapy studies of baricitinib<sup>33</sup> and upadacitinib<sup>34</sup> have found similar effectiveness to RCT data, and a small ( $n=23$ ) real-world study found comparable effectiveness between upadacitinib and dupilumab in paediatric AD at 24 weeks.<sup>35</sup> However, these agents have not yet been compared with conventional systemics in large, long-term studies. Mechanistic studies are also needed to further understand the factors underlying treatment responses to systemic AD therapies. These may, for instance, reveal immune or microbiome-based biomarkers to predict treatment response and allow for a more personalized approach to treating AD.

This real-world comparison of CyA, dupilumab and MTX in AD suggests that dupilumab is consistently more effective than MTX and that CyA is most effective in very severe disease. These findings should inform clinical practice and guide treatment decisions in paediatric and adult AD.

## Acknowledgements

We are grateful to all patients for their participation in the UK–Irish A-STAR register. This research was supported by the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (NIHR203308). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

## Funding sources

The British Association of Dermatologists Eczema Register Ltd (BADERL) is a registered not-for-profit company within the British Association of Dermatologists, which supports the UK–Irish Atopic eczema Systemic Therapy Register (A-STAR). A-STAR is coordinated by King's College London and Guy's and St Thomas' NHS Foundation Trust, London, UK. BADERL receives income from AbbVie, Eli Lilly and Pfizer for providing pharmacovigilance services on their therapies. The A-STAR study protocol, study conduct and all decisions concerning data analyses, interpretation and publication are made independent of any industry involvement.

## Conflicts of interest

The full conflicts of interest statement is provided in [Appendix 3](#).

## Data availability

The data underlying this article will be shared on reasonable request to the corresponding author.

## Ethics statement

The study is covered by Research ethics committee reference no. 18/WA/0200, ISRCTN 11210918.

## Patient consent

Not applicable.

## Supporting Information

Additional [Supporting Information](#) may be found in the online version of this article at the publisher's website.

## References

- Silverberg JI. Public health burden and epidemiology of atopic dermatitis. *Dermatol Clin* 2017; **35**:283–9.
- Drucker AM, Wang AR, Li W-Q *et al.* The burden of atopic dermatitis: summary of a report for the National Eczema Association. *J Invest Dermatol* 2017; **137**:26–30.
- Taylor K, Swan DJ, Affleck A *et al.* Treatment of moderate-to-severe atopic eczema in adults within the U.K.: results of a national survey of dermatologists. *Br J Dermatol* 2017; **176**:1617–23.
- Siegels D, Heratizadeh A, Abraham S *et al.* Systemic treatments in the management of atopic dermatitis: a systematic review and meta-analysis. *Allergy* 2021; **76**:1053–76.
- Ariëns LFM, Bakker DS, Spekhorst LS *et al.* Rapid and sustained effect of dupilumab on work productivity in patients with difficult-to-treat atopic dermatitis: results from the Dutch BioDay Registry. *Acta Derm Venereol* 2021; **101**:adv00573.
- Ariëns LFM, Schaft J, Bakker DS *et al.* Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: first clinical and biomarker results from the BioDay registry. *Allergy* 2020; **75**:116–26.
- Oosterhaven JAF, Spekhorst LS, Zhang J *et al.* Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab – a cross-sectional study from the BioDay registry. *J Dermatolog Treat* 2022; **33**:1986–9. <https://doi.org/10.1080/09546634.2021.1937485>.
- Faiz S, Giovannelli J, Podevin C *et al.* Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. *J Am Acad Dermatol* 2019; **81**:143–51.
- Lee H, Kim BR, Kim KH *et al.* One-year effectiveness and safety of dupilumab treatment for moderate-to-severe atopic dermatitis in Korean patients: a real-world retrospective analysis. *Allergy Asthma Immunol Res* 2022; **14**:117.
- Bosma AL, de Wijs LEM, Hof MH *et al.* Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: results of the TREAT NL (TREATment of ATopic eczema, the Netherlands) registry. *J Am Acad Dermatol* 2020; **83**:1375–84.
- El-Khalawany MA, Hassan H, Shaaban D *et al.* Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt. *Eur J Pediatr* 2013; **172**:351–6.
- Goujon C, Viguier M, Staumont-Sallé D *et al.* Methotrexate versus cyclosporine in adults with moderate-to-severe atopic dermatitis: a phase III randomized noninferiority trial. *J Allergy Clin Immunol Pract* 2018; **6**:562–9.e3.
- Gerbens LAA, Hamann SAS, Brouwer MWD *et al.* Methotrexate and azathioprine for severe atopic dermatitis: a 5-year follow-up study of a randomized controlled trial. *Br J Dermatol* 2018; **178**:1288–96.
- Bieber T, Simpson EL, Silverberg JI *et al.* Abrocitinib versus placebo or dupilumab for atopic dermatitis. *N Engl J Med* 2021; **384**:1101–12.
- Blauvelt A, Teixeira HD, Simpson EL *et al.* Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis. *JAMA Dermatol* 2021; **157**:1047.
- Spekhorst LS, Ariëns LFM, Schaft J *et al.* Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: results from the BioDay registry. *Allergy* 2020; **75**:2376–9.
- Drucker AM, Ellis AG, Bohdanowicz M *et al.* Systemic immunomodulatory treatments for patients with atopic dermatitis. *JAMA Dermatol* 2020; **156**:659.
- Silverberg JI, Thyssen JP, Fahrbach K *et al.* Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. *J Eur Acad Dermatol Venereol* 2021; **35**:1797–810.
- Drucker AM, Morra DE, Prieto-Merino D *et al.* Systemic immunomodulatory treatments for atopic dermatitis. *JAMA Dermatol* 2022; **158**:523.
- R Core Team. R: a language and environment for statistical computing. 2021. Available at: <https://www.r-project.org>.
- Wu JJ, Lafeuille M-H, Emond B *et al.* Real-world effectiveness of newly initiated systemic therapy for atopic dermatitis in the United States: a claims database analysis. *Adv Ther* 2022; **39**:4157–68.
- de Bruin-Weller M, Pink AE, Ferrucci SM *et al.* Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD). *J Dermatolog Treat* 2022; **33**:2565–70.
- Davis DMR, Drucker AM, Alikhan A *et al.* Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. *J Am Acad Dermatol* 2024; **90**:e43–56.
- Wollenberg A, Kinberger M, Arents B *et al.* European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy. *J Eur Acad Dermatol Venereol* 2022; **36**:1409–31.
- de Graaf M, Janmohamed SR, Schuttelaar MLA *et al.* Systemic treatment of children and adolescents with atopic dermatitis aged  $\geq$  2 years: a Delphi consensus project mapping expert opinion in Northern Europe. *J Eur Acad Dermatol Venereol* 2022; **36**:2153–65.
- Flohr C, Rosala-Hallas A, Jones AP *et al.* Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial. *Br J Dermatol* 2023; **189**:674–84.
- Londoño J, Perez L, Moreno S *et al.* Effectiveness and safety of dupilumab in adults with moderate and severe atopic dermatitis in Colombia: real-life experience. *World Allergy Org J* 2023; **16**:100763.
- National Institute for Health and Care Excellence. Dupilumab for treating moderate to severe atopic dermatitis. Technology appraisal guidance TA534. 2018. Available at: [www.nice.org.uk/guidance/ta534](http://www.nice.org.uk/guidance/ta534).
- Yang N, Ye Y, Shao J *et al.* Efficacy of dupilumab in children 6 months to 11 years old with atopic dermatitis: a retrospective

- real-world study in China. *Dermatitis* 2024; **35** (Suppl. 1):S39–46. <https://doi.org/10.1089/derm.2022.0069>.
- 30 Augustin M, Bauer A, Ertner K *et al.* Dupilumab demonstrates rapid onset of action in improving signs, symptoms and quality of life in adults with atopic dermatitis. *Dermatol Ther (Heidelb)* 2023; **13**:803–16.
- 31 Vittrup I, Krogh NS, Larsen HHP *et al.* A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: ineffectiveness in head-and-neck dermatitis. *J Eur Acad Dermatol Venereol* 2023; **37**:1046–55. <https://doi.org/10.1111/jdv.18849>.
- 32 Bosma AL, Ouwerkerk W, Heidema MJ *et al.* Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin types. *JAAD Int* 2023; **10**:14–24.
- 33 Hagino T, Saeki H, Fujimoto E, Kanda N. Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. *J Dermatol* 2023; **50**:869–79. <https://doi.org/10.1111/1346-8138.16763>.
- 34 Kosaka K, Uchiyama A, Ishikawa M *et al.* Real-world effectiveness and safety of upadacitinib in Japanese patients with atopic dermatitis: a two-centre retrospective study. *Eur J Dermatol* 2022; **32**:800–2.
- 35 Kiefer S, König A, Gerger V *et al.* Efficacy and treatment satisfaction of different systemic therapies in children and adolescents with moderate-to-severe atopic dermatitis: a real-world study. *J Clin Med* 2023; **12**:1175.

## Appendix 1 Author list with full list of affiliations

Helen Alexander,<sup>1</sup> Rayka Malek,<sup>1</sup> David Prieto-Merino,<sup>1,2</sup> Elizaveta Gribaleva,<sup>1</sup> Manisha Baden,<sup>1</sup> Paula Beattie,<sup>3</sup> Sara Brown,<sup>4</sup> Tim Burton,<sup>5</sup> Shona Cameron,<sup>1</sup> Bola Coker,<sup>6</sup> Michael J. Cork,<sup>7</sup> Ross Hearn,<sup>8</sup> John R. Ingram,<sup>9</sup> Alan D. Irvine,<sup>10,11,12</sup> Graham A. Johnston,<sup>13</sup> Alice Lambert,<sup>14</sup> Mark Lunt,<sup>15</sup> Irene Man,<sup>16</sup> Louise Newell,<sup>17</sup> Graham Ogg,<sup>18</sup> Prakash Patel,<sup>1</sup> Mandy Wan,<sup>19,20</sup> Richard B. Warren,<sup>21</sup> Richard Woolf,<sup>22</sup> Zenas Z.N. Yiu,<sup>21</sup> Nick Reynolds,<sup>23</sup> Michael R. Arden-Jones<sup>24</sup> and Carsten Flohr<sup>1</sup> on behalf of the UK–Irish A-STAR study group

<sup>1</sup>Unit for Paediatric & Population-Based Dermatology Research, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, UK

<sup>2</sup>Faculty of Medicine, University of Alcalá, Alcalá de Henares, Spain

<sup>3</sup>Department of Dermatology, Royal Hospital for Children NHS Trust, Glasgow, UK

<sup>4</sup>Centre for Genomic and Experimental Medicine, University of Edinburgh, Edinburgh, UK

<sup>5</sup>Patient representative (independent), Nottingham, UK

<sup>6</sup>Research and Development Department, Guy's and St Thomas' NHS Foundation Trust, London, UK

<sup>7</sup>Sheffield Dermatology Research, University of Sheffield, Sheffield, UK

<sup>8</sup>Department of Dermatology and Photobiology, Ninewells Hospital, Dundee, UK

<sup>9</sup>Department of Dermatology, Division of Infection & Immunity, Cardiff University, Cardiff, UK

<sup>10</sup>Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland

<sup>11</sup>Dermatology, Children's Health Ireland, Crumlin, Ireland

<sup>12</sup>National Children's Research Centre, Dublin, Ireland

<sup>13</sup>Department of Dermatology, University Hospitals of Leicester NHS Trust, Leicester, UK

<sup>14</sup>National Eczema Society, London, UK

<sup>15</sup>Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester, UK

<sup>16</sup>Department of Dermatology, Surrey and Sussex Healthcare NHS Trust, Surrey, UK

<sup>17</sup>Paediatric Dermatology, Bristol Royal Hospital for Children, Bristol, UK

<sup>18</sup>MRC Translational Immune Discovery Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford

<sup>19</sup>Evelina London Children's Hospital, Guys' & St Thomas' NHS Foundation Trust, London, UK

<sup>20</sup>Institute of Pharmaceutical Science, King's College London, London, UK

<sup>21</sup>Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester; Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK

<sup>22</sup>St John's Institute of Dermatology, King's College London, London, UK

<sup>23</sup>Institute of Translational and Clinical Medicine, Newcastle University Medical School and Department of Dermatology; and the Newcastle NIHR Biomedical Research Centre, Royal Victoria Infirmary, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK

<sup>24</sup>Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton, UK

## Appendix 2 A-STAR study group members

Michael R. Arden-Jones, Paula Beattie, Sara Brown, Victoria Brown, Michael J. Cork, Sharmela Darné, May Fadhil, Caoimhe Fahy, Leila Ferguson, Carsten Flohr, Ross Hearn, John R. Ingram, Graham A. Johnston, Effi Ladoyanni, Alison Layton, Claire Leitch, Joanne Llewellyn, Mark Lunt, Irene Man, Louise Newell, Graham Ogg, Urvi Popli, Nick Reynolds, Ann Sergeant, Ben Thompson, Joanne Topliffe, Shyamal Wahie, Hannah Wainman, Richard B. Warren, Aaron Wernham, Richard Woolf, Zenas Z.N. Yiu.

## Appendix 3 Full list of authors' conflicts of interest

J.R.I. received a stipend as Editor-in-Chief of the *British Journal of Dermatology* (at the time of submission) and an authorship honorarium from UpToDate; he is a consultant for AbbVie, Boehringer Ingelheim, ChemoCentryx, Citryll, MoonLake, Novartis, UCB Pharma and UNION Therapeutics and has served on advisory boards for Insmad, Kymera Therapeutics and Viela Bio; his department receives income from the copyright of the Dermatology Life Quality Instrument (DLQI) and related instruments; he is treasurer of the CHORD-COUSIN Collaboration (C3) dermatology outcomes consortium. A.D.I. has received honoraria for consultancy from AbbVie, Arena Pharmaceuticals, Aslan, BenevolentAI, Chugai, Dermavant,

Genentech, LEO Pharma, Lilly, Menlo Therapeutics, Novartis, Pfizer, Regeneron and Sanofi.

G.A.J. has received educational grants from Sanofi-Genzyme. G.O. holds patents relevant to inflammatory skin disease. Research funds are administered through his institution from Janssen and UCB. M.R.A.-J. has received speaker, adviser, honoraria, travel/research/departmental grants from AbbVie, Almirall, Amgen, Ducentis, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi, UCB and Unilever. C.F. is chief investigator of the UK National Institute for Health Research-funded

TREAT (ISRCTN15837754) and SOFTER ([Clinicaltrials.gov: NCT03270566](https://clinicaltrials.gov/ct2/show/study/NCT03270566)) trials as well as the UK–Irish Atopic eczema Systemic Therapy Register (A-STAR; ISRCTN11210918) and a principal investigator in the European Union (EU) Horizon 2020-funded BIOMAP Consortium (<http://www.biomap-imi.eu/>); he also leads the EU Trans-Foods consortium; his department has received funding from Pfizer and Sanofi-Genzyme for skin microbiome work; he has also received compensation from the *British Journal of Dermatology* (reviewer and section editor) and EuroGuiDerm (guidelines lead). All other authors declare no conflicts of interest.

# Consistent safety profile with over 8 years of real-world evidence, across licensed indications<sup>1-3</sup>



**1,000,000** patients treated globally, and counting across indications<sup>4</sup>



**150+**  
clinical trials  
across indications<sup>5</sup>



**8+ years** of real-world  
evidence, worldwide  
across indications<sup>1-3</sup>



**8**  
indications<sup>1-3</sup>



**Click here to visit  
our HCP portal  
and learn more**

## Real-world evidence shows a consistent safety profile with long-term use of Cosentyx over 6 years<sup>6,7</sup>

No trend toward increased AE rates over time (pooled PsA, AS, PsO):\*<sup>6</sup>

AEs of select interest (EAIR per 100 PY)	1 year	2 years	3 years	4 years	5 years	6 years	Cumulative rate
Serious infections Cases	2.0 n=149	1.7 n=475	0.7 n=649	1.3 n=1,841	1.3 n=2,285	1.1 n=2,226	1.3 n=8,719
Malignant or unspecified tumours Cases	0.2 n=15	0.2 n=50	0.2 n=225	0.3 n=422	0.3 n=520	0.3 n=573	0.3 n=1,896
MACE Cases	0.2 n=15	0.1 n=39	0.2 n=151	0.2 n=238	0.2 n=264	0.1 n=287	0.2 n=1,031
Total IBD Cases	0.2 n=12	0.2 n=46	0.2 n=185	0.3 n=340	0.2 n=312	0.1 n=261	0.2 n=1,291
Exposure (PY)	7,450	28,549	93,744	137,325	182,024	212,636	680,470

**No trend towards increased rates of malignancy, MACE or IBD over time<sup>6</sup>**

**The most frequently reported adverse reactions are upper respiratory tract infections (17.1%) (most frequently nasopharyngitis, rhinitis).<sup>1,2</sup> Refer to the prescribing information for a summary of adverse events.**

Adapted from Novartis Data on File. 2021.<sup>6</sup>

**Refer to the Cosentyx Summary of Product Characteristics for full details, dosing and administration, including special populations.**

Cosentyx is indicated for the treatment of moderate to severe **PsO** in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active **PsA** in adult patients (alone or in combination with methotrexate) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active **AS** in adults who have responded inadequately to conventional therapy; active **nr-axSpA** with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe **HS** (acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active **ERA** in patients 6 years and older (alone or in combination with methotrexate) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active **JPsA** in patients 6 years and older (alone or in combination with methotrexate) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.<sup>1,2</sup>

**Prescribing information, adverse event reporting and full indication can be found on the next page.**

\*Successive time periods of PSUR shown with cumulative rate: 26 Dec 2014 to 25 Dec 2015; 26 Dec 2015 to 25 Dec 2016; 26 Dec 2016 to 25 Dec 2017; 26 Dec 2017 to 25 Dec 2018; 26 Dec 2018 to 25 Dec 2019; 26 Dec 2019 to 25 Dec 2020.<sup>6</sup>

**Abbreviations:** AE, adverse event; AS, ankylosing spondylitis; EAIR, exposure-adjusted incidence rate; ERA, enthesitis-related arthritis; HCP, healthcare professional; HS, hidradenitis suppurativa; IBD, inflammatory bowel disease; JPsA, juvenile psoriatic arthritis; MACE, major adverse cardiac event; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis; PsO, plaque psoriasis; PY, patient year.

**References:** 1. Cosentyx® (secukinumab) GB Summary of Product Characteristics; 2. Cosentyx® (secukinumab) NI Summary of Product Characteristics; 3. European Medicines Agency. European public assessment report. Available at: [https://www.ema.europa.eu/en/documents/overview/cosentyx-epar-medicine-overview\\_en.pdf](https://www.ema.europa.eu/en/documents/overview/cosentyx-epar-medicine-overview_en.pdf) [Accessed August 2024]; 4. Novartis Data on File. Secukinumab – Sec008. 2023; 5. ClinicalTrials.gov. Search results for 'secukinumab', completed, terminated and active, not recruiting trials. Available at: <https://clinicaltrials.gov/search?term=Secukinumab.&aggFilters=status.com> [Accessed August 2024]; 6. Novartis data on file. Cosentyx Periodic Safety Update Report (PSUR); 26 December 2019 – 25 December 2020. 22 February 2021; 7. Deodhar A, et al. Arthritis Res Ther 2019;21(1):111.



Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard)  
 Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report) or alternatively email [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com) or call 01276 698370.

## **Cosentyx® (secukinumab) Northern Ireland Prescribing Information.**

### **Please refer to the Summary of Product Characteristics (SmPC) before prescribing.**

**Indications:** Treatment of: moderate to severe plaque psoriasis in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adults (alone or in combination with methotrexate) who have responded inadequately to disease-modifying anti-rheumatic drug therapy; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active enthesitis-related arthritis and juvenile psoriatic arthritis in patients 6 years and older (alone or in combination with methotrexate) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy. **Presentations:** Cosentyx 150 mg solution for injection in pre-filled pen; Cosentyx 300 mg solution for injection in pre-filled pen. **Dosage & Administration:** Administered by subcutaneous injection at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Consider discontinuation if no response after 16 weeks of treatment. Each 150 mg dose is given as one injection of 150 mg. Each 300 mg dose is given as two injections of 150 mg or one injection of 300 mg. If possible avoid areas of the skin showing psoriasis. **Plaque Psoriasis:** Adult recommended dose is 300 mg monthly. Based on clinical response, a maintenance dose of 300 mg every 2 weeks may provide additional benefit for patients with a body weight of 90 kg or higher. Adolescents and children from the age of 6 years: if weight  $\geq$  50 kg, recommended dose is 150 mg (may be increased to 300 mg as some patients may derive additional benefit from the higher dose). If weight < 50 kg, recommended dose is 75 mg. However, 150mg solution for injection in pre-filled pen is not indicated for administration of this dose and no suitable alternative formulation is available. **Psoriatic Arthritis:** For patients with concomitant moderate to severe plaque psoriasis see adult plaque psoriasis recommendation. For patients who are anti-TNF $\alpha$  inadequate responders, the recommended dose is 300 mg, 150 mg in other patients. Can be increased to 300 mg based on clinical response. **Ankylosing Spondylitis:** Recommended dose 150 mg. Can be increased to 300 mg based on clinical response. **nr-axSpA:** Recommended dose 150 mg. **Enthesitis-related arthritis and juvenile psoriatic arthritis:** From the age of 6 years, if weight  $\geq$  50 kg, recommended dose is 150 mg. If weight < 50 kg, recommended dose is 75 mg. However, 150mg

## **Cosentyx® (secukinumab) Great Britain Prescribing Information.**

### **Please refer to the Summary of Product Characteristics (SmPC) before prescribing.**

**Indications:** Treatment of: moderate to severe plaque psoriasis in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adults (alone or in combination with methotrexate) who have responded inadequately to disease-modifying anti-rheumatic drug therapy; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active enthesitis-related arthritis and juvenile psoriatic arthritis in patients 6 years and older (alone or in combination with methotrexate) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy. **Presentations:** Cosentyx 75 mg solution for injection in pre-filled syringe; Cosentyx 150 mg solution for injection in pre-filled pen; Cosentyx 150 mg solution for injection in pre-filled pen; Cosentyx 300 mg solution for injection in pre-filled pen. **Dosage & Administration:** Administered by subcutaneous injection at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Consider discontinuation if no response after 16 weeks of treatment. Each 75 mg dose is given as one injection of 75 mg. Each 150 mg dose is given as one injection of 150 mg. Each 300 mg dose is given as two injections of 150 mg or one injection of 300 mg. If possible avoid areas of the skin showing psoriasis. **Plaque Psoriasis:** Adult recommended dose is 300 mg. Based on clinical response, a maintenance dose of 300 mg every 2 weeks may provide additional benefit for patients with a body weight of 90 kg or higher. Adolescents and children from the age of 6 years: if weight  $\geq$  50 kg, recommended dose is 150 mg (may be increased to 300 mg as some patients may derive additional benefit from the higher dose). If weight < 50 kg, recommended dose is 75 mg. **Psoriatic Arthritis:** For patients with concomitant moderate to severe plaque psoriasis see adult plaque psoriasis recommendation. For patients who are anti-TNF $\alpha$  inadequate responders, the recommended dose is 300 mg, 150 mg in other patients. Can be increased to 300 mg based on clinical response. **Ankylosing Spondylitis:** Recommended dose 150 mg. Can be increased to 300 mg based on clinical response. **nr-axSpA:** Recommended dose 150 mg. **Enthesitis-related arthritis and juvenile psoriatic arthritis:** From the age of 6 years, if weight  $\geq$  50 kg, recommended dose is 150 mg. If weight < 50 kg, recommended dose is 75 mg. **Hidradenitis suppurativa:**

solution for injection in pre-filled pen is not indicated for administration of this dose and no suitable alternative formulation is available. **Hidradenitis suppurativa:** Recommended dose is 300 mg monthly. Based on clinical response, the maintenance dose can be increased to 300 mg every 2 weeks. **Contraindications:** Hypersensitivity to the active substance or excipients. Clinically important, active infection. **Warnings & Precautions:** **Infections:** Potential to increase risk of infections; serious infections have been observed. Caution in patients with chronic infection or history of recurrent infection. Advise patients to seek medical advice if signs/symptoms of infection occur. Monitor patients with serious infection closely and do not administer Cosentyx until the infection resolves. Non-serious mucocutaneous candida infections were more frequently reported for secukinumab than placebo in the psoriasis clinical studies. Should not be given to patients with active tuberculosis (TB). Consider anti-tuberculosis therapy before starting Cosentyx in patients with latent TB. **Inflammatory bowel disease (including Crohn's disease and ulcerative colitis):** New cases or exacerbations of inflammatory bowel disease have been reported with secukinumab. Secukinumab, is not recommended in patients with inflammatory bowel disease. If a patient develops signs and symptoms of inflammatory bowel disease or experiences an exacerbation of pre-existing inflammatory bowel disease, secukinumab should be discontinued and appropriate medical management should be initiated. **Hypersensitivity reactions:** Rare cases of anaphylactic reactions have been observed. If an anaphylactic or serious allergic reactions occur, discontinue immediately and initiate appropriate therapy. **Vaccinations:** Do not give live vaccines concurrently with Cosentyx; inactivated or non-live vaccinations may be given. Paediatric patients should receive all age appropriate immunisations before treatment with Cosentyx. **Latex-Sensitive Individuals:** The removable needle cap of the 150mg pre-filled pen contains a derivative of natural rubber latex. **Concomitant immunosuppressive therapy:** Combination with immunosuppressants, including biologics, or phototherapy has not been evaluated in psoriasis studies. Cosentyx was given concomitantly with methotrexate, sulfasalazine and/or corticosteroids in arthritis studies. Caution when considering concomitant use of other immunosuppressants. **Interactions:** Live vaccines should not be given concurrently with secukinumab. No interaction between Cosentyx and midazolam (CYP3A4 substrate) seen in adult psoriasis study. No interaction between Cosentyx and methotrexate and/or corticosteroids seen in arthritis studies. **Fertility, pregnancy and lactation:** **Women of childbearing potential:** Use an effective method of contraception during and for at least 20 weeks after treatment. **Pregnancy:** Preferably avoid use of Cosentyx in pregnancy. **Breast feeding:** It is not known if secukinumab is excreted in human breast milk. A clinical decision should be made on continuation of breast feeding during Cosentyx treatment (and up to 20 weeks after discontinuation) based on benefit

Recommended dose is 300 mg monthly. Based on clinical response, the maintenance dose can be increased to 300 mg every 2 weeks. **Contraindications:** Hypersensitivity to the active substance or excipients. Clinically important, active infection. **Warnings & Precautions:** **Infections:** Potential to increase risk of infections; serious infections have been observed. Caution in patients with chronic infection or history of recurrent infection. Advise patients to seek medical advice if signs/symptoms of infection occur. Monitor patients with serious infection closely and do not administer Cosentyx until the infection resolves. Non-serious mucocutaneous candida infections were more frequently reported for secukinumab in the psoriasis clinical studies. Should not be given to patients with active tuberculosis (TB). Consider anti-tuberculosis therapy before starting Cosentyx in patients with latent TB. **Inflammatory bowel disease (including Crohn's disease and ulcerative colitis):** New cases or exacerbations of inflammatory bowel disease have been reported with secukinumab. Secukinumab, is not recommended in patients with inflammatory bowel disease. If a patient develops signs and symptoms of inflammatory bowel disease or experiences an exacerbation of pre-existing inflammatory bowel disease, secukinumab should be discontinued and appropriate medical management should be initiated. **Hypersensitivity reactions:** Rare cases of anaphylactic reactions have been observed. If an anaphylactic or serious allergic reactions occur, discontinue immediately and initiate appropriate therapy. **Vaccinations:** Do not give live vaccines concurrently with Cosentyx; inactivated or non-live vaccinations may be given. Paediatric patients should receive all age appropriate immunisations before treatment with Cosentyx. **Latex-Sensitive Individuals:** The removable needle cap of the 75mg and 150 mg pre-filled syringe and 150mg pre-filled pen contains a derivative of natural rubber latex. **Concomitant immunosuppressive therapy:** Combination with immunosuppressants, including biologics, or phototherapy has not been evaluated in psoriasis studies. Cosentyx was given concomitantly with methotrexate, sulfasalazine and/or corticosteroids in arthritis studies. Caution when considering concomitant use of other immunosuppressants. **Interactions:** Live vaccines should not be given concurrently with secukinumab. No interaction between Cosentyx and midazolam (CYP3A4 substrate) seen in adult psoriasis study. No interaction between Cosentyx and methotrexate and/or corticosteroids seen in arthritis studies. **Fertility, pregnancy and lactation:** **Women of childbearing potential:** Use an effective method of contraception during and for at least 20 weeks after treatment. **Pregnancy:** Preferably avoid use of Cosentyx in pregnancy. **Breast feeding:** It is not known if secukinumab is excreted in human breast milk. A clinical decision should be made on continuation of breast feeding during Cosentyx treatment (and up to 20 weeks after discontinuation) based on benefit of breast feeding to the child and benefit of Cosentyx therapy to the woman. **Fertility:** Effect on human fertility not evaluated. **Adverse**

of breast feeding to the child and benefit of Cosentyx therapy to the woman. **Fertility:** Effect on human fertility not evaluated. **Adverse Reactions:** **Very Common ( $\geq$ 1/10):** Upper respiratory tract infection. **Common ( $\geq$ 1/100 to <1/10):** Oral herpes, headache, rhinorrhoea, diarrhoea, nausea, fatigue. **Uncommon ( $\geq$ 1/1,000 to <1/100):** Oral candidiasis, lower respiratory tract infections, neutropenia, inflammatory bowel disease. **Rare ( $\geq$ 1/10,000 to <1/1,000):** anaphylactic reactions, exfoliative dermatitis (psoriasis patients), hypersensitivity vasculitis. **Not known:** Mucosal and cutaneous candidiasis (including oesophageal candidiasis). **Infections:** Most infections were non-serious and mild to moderate upper respiratory tract infections, e.g. nasopharyngitis, and did not necessitate treatment discontinuation. There was an increase in mucosal and cutaneous (including oesophageal) candidiasis, but cases were mild or moderate in severity, non-serious, responsive to standard treatment and did not necessitate treatment discontinuation. Serious infections occurred in a small proportion of patients (0.015 serious infections reported per patient year of follow up). **Neutropenia:** Neutropenia was more frequent with secukinumab than placebo, but most cases were mild, transient and reversible. Rare cases of neutropenia CTCAE Grade 4 were reported. **Hypersensitivity reactions:** Urticaria and rare cases of anaphylactic reactions were seen. **Immunogenicity:** Less than 1% of patients treated with Cosentyx developed antibodies to secukinumab up to 52 weeks of treatment. **Other Adverse Effects:** The list of adverse events is not exhaustive, please consult the SmPC for a detailed listing of all adverse events before prescribing. **Legal Category:** POM. **MA Number & List Price:** EU/1/14/980/005 - 150 mg pre-filled pen x2 £1,218.78; EU/1/14/980/010 - 300 mg pre-filled pen x1 £1218.78. **PL Last Revised:** May 2023. Full prescribing information, (SmPC) is available from: Novartis Pharmaceuticals UK Limited, 2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ. Telephone: (01276) 692255.

UK I 284832 | May 2023

#### **Adverse Event Reporting:**

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Novartis via [uk.patientsafety@novartis.com](mailto:uk.patientsafety@novartis.com) or online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report). If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com)

**Reactions:** **Very Common ( $\geq$ 1/10):** Upper respiratory tract infection. **Common ( $\geq$ 1/100 to <1/10):** Oral herpes, headache, rhinorrhoea, diarrhoea, nausea, fatigue. **Uncommon ( $\geq$ 1/1,000 to <1/100):** Oral candidiasis, lower respiratory tract infections, neutropenia, inflammatory bowel disease. **Rare ( $\geq$ 1/10,000 to <1/1,000):** anaphylactic reactions, exfoliative dermatitis (psoriasis patients), hypersensitivity vasculitis. **Not known:** Mucosal and cutaneous candidiasis (including oesophageal candidiasis). **Infections:** Most infections were non-serious and mild to moderate upper respiratory tract infections, e.g. nasopharyngitis, and did not necessitate treatment discontinuation. There was an increase in mucosal and cutaneous (including oesophageal) candidiasis, but cases were mild or moderate in severity, non-serious, responsive to standard treatment and did not necessitate treatment discontinuation. Serious infections occurred in a small proportion of patients (0.015 serious infections reported per patient year of follow up). **Neutropenia:** Neutropenia was more frequent with secukinumab than placebo, but most cases were mild, transient and reversible. Rare cases of neutropenia CTCAE Grade 4 were reported. **Hypersensitivity reactions:** Urticaria and rare cases of anaphylactic reactions were seen. **Immunogenicity:** Less than 1% of patients treated with Cosentyx developed antibodies to secukinumab up to 52 weeks of treatment. **Other Adverse Effects:** The list of adverse events is not exhaustive, please consult the SmPC for a detailed listing of all adverse events before prescribing. **Legal Category:** POM. **MA Number & List Price:** PLGB 00101/1205 - 75 mg pre-filled syringe x 1 - £304.70; PLGB 00101/1029 - 150 mg pre-filled pen x2 £1,218.78; PLGB 00101/1030 - 150 mg pre-filled syringe x2 £1,218.78; PLGB 00101/1198 - 300 mg pre-filled pen x1 £1218.78. **PL Last Revised:** June 2023. Full prescribing information, (SmPC) is available from: Novartis Pharmaceuticals UK Limited, 2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ. Telephone: (01276) 692255.

UK I 290802 | June 2023

#### **Adverse Event Reporting:**

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Novartis via [uk.patientsafety@novartis.com](mailto:uk.patientsafety@novartis.com) or online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report). If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com)